E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.

Enter your email address:

Delivered by FeedBurner

Contact the Docs

Docs on Twitter


About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.

Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.

  • Law Blogs

Become a Fan

« USPTO Peer to Patent Program Expanded to Include Biotech Patent Applications | Main | Bayer Submits Brief in Therasense v. Becton Dickinson »

October 20, 2010

TrackBack

TrackBack URL for this entry:
http://www.typepad.com/services/trackback/6a00d83451ca1469e20134885aaafa970c

Listed below are links to weblogs that reference GSK Forms Alliance for Development of Gene Therapy Techniques for Rare Diseases:

Comments

WHEN WILL WE KNOW WHAT THE 200 RARE DISEASES ARE? BEING THAT GSK IS A PHARMACEUDICAL, WILL GSK BE LOOKING TO TREAT THE CAUSE OF THE DISEASE OR THE SYMPTOMS? WILL ADRENOLEUKODYSTROPHY/ADRENOMYELONEUROPATHY BE ONE OF THE 200 DISEASES?

The comments to this entry are closed.

August 2014

Sun Mon Tue Wed Thu Fri Sat
          1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30
31